Downloads
Abstract
Objective: Evaluating toxicities of R-CHOP in treating Diffused large B cell Non Hodgkin Lymphoma with CD20+ at Hue Central Hospital.
Methods: progressive descriptive study on 37 patients diagnosed with Diffused large B cell Non Hodgkin Lymphoma with CD20+ at Hue Central Hospital from 03/2017 to 06/2020. Toxicities were evaluated by WHO grading system. Data were analyzed by medical statistics algorithms SPSS 20.0.
Results: Neutropenia was 70.2%, grade IV was 13.5%. Elevated SGOT and SGPT were 35.1% and 21.6%, respectively, including 5.4% with elevated common transaminase. Other adverse effects including nausea - vomiting, alopecia, diarrhea, mucositis and cardiac toxicity were 67.6%, 100%, 5.4%, 8.1% and 13.5%, respectively. There were two patients with hypersensitivity on Rituximab at the first infusion (5.4%), including one grade I and one grade III, there was no hypersensitivity in the later infusions. Rate of HBV-reactive in HbSAg (-) and HbSAg (+) were 8.0% and 8.3%, respectively.
Conclusions: First line R-CHOP for Diffused large B cell Non Hodgkin Lymphoma with CD20+ is an effective regimen with good response, uncommon and less toxicities.
References
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H,
Siebert R, et al. The 2016 revision of the World Health
Organization classification of lymphoid neoplasms. Blood.
May 19;127(20):2375-90.
Li S, Young KH, Medeiros LJ. Diffuse large B-cell
lymphoma. Pathology (Phila). 2018 Jan;50(1):74-87.
Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H,
Bouabdallah R, et al. CHOP Chemotherapy plus Rituximab
Compared with CHOP Alone in Elderly Patients with
Diffuse Large-B-Cell Lymphoma. N Engl J Med. 2002 Jan
;346(4):235-42.
Grillo - Lopez A, White C, Dallaire B, Varns C, Shen C,
Wei A, et al. Rituximab The First Monoclonal Antibody
Approved for the Treatment of Lymphoma. Curr Pharm
Biotechnol. 2000 Jul 1;1(1):1-9.
Choi YW, Jeong SH, Ahn MS, Lee HW, Kang SY, Choi
JH, et al. Patterns of Neutropenia and Risk Factors for
Febrile Neutropenia of Diffuse Large B-Cell Lymphoma
Patients Treated with Rituximab-CHOP. J Korean Med Sci.
;29(11):1493.
Feugier P, Van Hoof A, Sebban C, Solal-Celigny P,
Bouabdallah R, Fermé C, et al. Long - Term Results of the
R-CHOP Study in the Treatment of Elderly Patients With
Diffuse Large B-Cell Lymphoma: A Study by the Groupe
d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005
Jun 20;23(18):4117-26.
Yokoyama M, Kusano Y, Takahashi A, Inoue N, Ueda
K, Nishimura N, et al. Incidence and risk factors of
febrile neutropenia in patients with non - Hodgkin B-cell
lymphoma receiving R-CHOP in a single center in Japan.
Support Care Cancer. 2017 Nov;25(11):3313-20.
Ray - Coquard I, Borg C, Bachelot T, Sebban C, Philip I,
et al. Baseline and early lymphopenia predict for the risk of
febrile neutropenia after chemotherapy. Br J Cancer. 2003
Jan;88(2):181-6.
Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T,
Fan E, et al. A systematic literature review of the efficacy,
effectiveness, and safety of filgrastim. Support Care
Cancer Off J Multinatl Assoc Support Care Cancer. 2018
Jan;26(1):7-20.
Dunnill CJ, Al - Tameemi W, Collett A, Haslam IS,
Georgopoulos NT. A Clinical and Biological Guide for
Understanding Chemotherapy-Induced Alopecia and Its
Prevention. The Oncologist. 2018 Jan 1;23(1):84-96.
Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth
JD, Harker G, et al. Proposal for classifying the acute
emetogenicity of cancer chemotherapy. J Clin Oncol. 1997
Jan;15(1):103-9.
Di Renzo N, Montanini A, Mannina D, Dondi A, Muci S,
Mancuso S, et al. Single - dose palonosetron for prevention
of chemotherapy - induced nausea and vomiting in patients
with aggressive non - Hodgkin’s lymphoma receiving
moderately emetogenic chemotherapy containing steroids:
results of a phase II study from the Gruppo Italiano per lo
Studio dei Linfomi (GISL). Support Care Cancer. 2011
Oct;19(10):1505-10.
Takahashi T, Okada T, Ikejiri F, Ito S, Okada Y, Takahashi
F, et al. A prospective study of palonosetron for prevention
of chemotherapy - induced nausea and vomiting in
malignant lymphoma patients following highly emetogenic
chemotherapy. Int J Clin Oncol. 2018 Feb;23(1):189-94.
Takahashi T, Kumanomidou S, Takami S, Okada T, Adachi
K, Jo Y, et al. A retrospective study of R-CHOP/CHOP
therapy-induced nausea and vomiting in non-Hodgkin’s
lymphoma patients: a comparison of intravenous and
oral 5-HT3 receptor antagonists. Int J Hematol. 2016
Sep;104(3):378-83.
Fridrik MA, Jaeger U, Petzer A, Willenbacher W, Keil F, Lang
A, et al. Cardiotoxicity with rituximab, cyclophosphamide,
non-pegylated liposomal doxorubicin, vincristine and
prednisolone compared to rituximab, cyclophosphamide,
doxorubicin, vincristine, and prednisolone in frontline
treatment of patients with diffuse large B-cell lymphoma.
Eur J Cancer. 2016 May;58:112-21.
Mizia - Stec K, Elżbieciak M, Wybraniec MT, Różewicz
M, Bodys A, Braksator W, et al. Chemotherapy and
echocardiographic indices in patients with non-Hodgkin
lymphoma: the ONCO - ECHO study. Med Oncol. 2018
Jan;35(1):14.
Levin AS, Otani IM, Lax T, Hochberg E, Banerji A.
Reactions to Rituximab in an Outpatient Infusion Center:
A 5-Year Review. J Allergy Clin Immunol Pract. 2017
Jan;5(1):107-113.e1.
Phan Thị Phượng. Nghiên cứu kết quả điều trị một số dưới
nhóm u lympho ác tính không Hodgkin tế bào B lớn lan tỏa
bằng phác đồ R - CHOP tại Bệnh viện Bạch Mai năm 2015
- 2017, Luận văn Thạc sĩ y học, Đại học Y Hà Nội; 2017.
Phùng Phướng, Nguyễn Thị Thuỷ. Nghiên cứu tình hình
hoạt hoá viêm gan B và các yếu tố liên quan ở bệnh nhân
hoá trị. J Med Pharm. 2016 Mar;74-80.
Myint A, Tong MJ, Beaven SW. Reactivation of Hepatitis
B Virus: A Review of Clinical Guidelines. Clin Liver Dis.
Apr;15(4):162-7.
Merli M, Rattotti S, Gotti M, Arcaini L. Antiviral therapies
for managing viral hepatitis in lymphoma patients. Expert
Opin Pharmacother. 2017 Mar 4;18(4):363-76.
Picardi M, Pepa RD, Giordano C, Zacheo I, Mortaruolo
C, Trastulli F, et al. Tenofovir versus lamivudine for the
prevention of hepatitis B virus reactivation in advancedstage DLBCL.
| Published | 20-08-2023 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 89 (2023) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.89.18 | |
| Keywords | Phác đồ R-CHOP, u lympho ác tính không Hodgkin, tế bào B lớn lan tỏa, độc tính. : R-CHOP, malignant Non Hodgkin Lymphoma, Diffused large B cell, toxicity |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Journal of Clinical Medicine Hue Central Hospital